{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:45:08Z","timestamp":1790279108118,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013124","name":"Brittle Bone Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00198-020-05755-9","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T06:04:15Z","timestamp":1609999455000},"page":"1207-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hospital admissions of patients with osteogenesis imperfecta in the English NHS"],"prefix":"10.1007","volume":"32","author":[{"given":"S.","family":"Kolovos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-5128","authenticated-orcid":false,"given":"R.","family":"Pinedo-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"6","key":"5755_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164a","author":"FS Van Dijk","year":"2014","unstructured":"Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 164a(6):1470\u20131481. https:\/\/doi.org\/10.1002\/ajmg.a.36545","journal-title":"Am J Med Genet A"},{"key":"5755_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bone.2017.02.004","volume":"102","author":"J Lim","year":"2017","unstructured":"Lim J, Grafe I, Alexander S, Lee B (2017) Genetic causes and mechanisms of osteogenesis imperfecta. Bone 102:40\u201349","journal-title":"Bone"},{"issue":"2","key":"5755_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00198-018-4801-5","volume":"30","author":"Y Song","year":"2019","unstructured":"Song Y, Zhao D, Li L, Lv F, Wang O, Jiang Y, Xia W, Xing X, Li M (2019) Health-related quality of life in children with osteogenesis imperfecta: a large-sample study. Osteoporos Int 30(2):461\u2013468. https:\/\/doi.org\/10.1007\/s00198-018-4801-5","journal-title":"Osteoporos Int"},{"issue":"1","key":"5755_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12887-018-1077-z","volume":"18","author":"AP Vanz","year":"2018","unstructured":"Vanz AP, van de Sande Lee J, Pinheiro B, Zambrano M, Brizola E, da Rocha NS, Schwartz IVD, de Souza Pires MM, Felix TM (2018) Health-related quality of life of children and adolescents with osteogenesis imperfecta: a cross-sectional study using PedsQL. BMC Pediatr 18(1):95. https:\/\/doi.org\/10.1186\/s12887-018-1077-z","journal-title":"BMC Pediatr"},{"issue":"5","key":"5755_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00223-017-0301-4","volume":"101","author":"JD Hald","year":"2017","unstructured":"Hald JD, Folkestad L, Harslof T, Brixen K, Langdahl B (2017) Health-related quality of life in adults with osteogenesis imperfecta. Calcif Tissue Int 101(5):473\u2013478. https:\/\/doi.org\/10.1007\/s00223-017-0301-4","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"5755_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00774-019-01033-9","volume":"38","author":"M Matsushita","year":"2020","unstructured":"Matsushita M, Mishima K, Yamashita S, Haga N, Fujiwara S, Ozono K, Kubota T, Kitaoka T, Ishiguro N, Kitoh H (2020) Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta. J Bone Miner Metab 38(1):109\u2013116. https:\/\/doi.org\/10.1007\/s00774-019-01033-9","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"5755_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","volume":"11","author":"L Forestier-Zhang","year":"2016","unstructured":"Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C, Eastell R, Wordsworth P, Javaid MK, Pinedo-Villanueva R (2016) Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis 11(1):160. https:\/\/doi.org\/10.1186\/s13023-016-0538-4","journal-title":"Orphanet J Rare Dis"},{"key":"5755_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrendo.2011.81","volume":"7","author":"A Forlino","year":"2011","unstructured":"Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540. https:\/\/doi.org\/10.1038\/nrendo.2011.81","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"5755_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/ije\/dyx015","volume":"46","author":"A Herbert","year":"2017","unstructured":"Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P (2017) Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol 46(4):1093\u20131093i. https:\/\/doi.org\/10.1093\/ije\/dyx015","journal-title":"Int J Epidemiol"},{"key":"5755_CR10","unstructured":"Health and Social Care Information Centre Hospital Episode Statistics. https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics. Accessed\u00a0June 2020"},{"key":"5755_CR11","unstructured":"NHS England (2016) Supplementary technical definitions 2016\/17: Activity"},{"key":"5755_CR12","unstructured":"Health and Social Care Information Centre (2018) HES data dictionary: admitted patient care"},{"key":"5755_CR13","unstructured":"The National Casemix Classifications Service (2009) Guide to unbundling"},{"key":"5755_CR14","unstructured":"Clinical Classifications Service (2017) National clinical coding standards OPCS-4. Health and Social Care Information Centre"},{"key":"5755_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13023-015-0362-2","volume":"10","author":"LL Tosi","year":"2015","unstructured":"Tosi LL, Oetgen ME, Floor MK, Huber MB, Kennelly AM, McCarter RJ, Rak MF, Simmonds BJ, Simpson MD, Tucker CA, McKiernan FE (2015) Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis 10:146. https:\/\/doi.org\/10.1186\/s13023-015-0362-2","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"5755_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F, Travers R, Glorieux FH (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40(3):638\u2013644. https:\/\/doi.org\/10.1016\/j.bone.2006.10.010","journal-title":"Bone"},{"issue":"14","key":"5755_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/nejm199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947\u2013952. https:\/\/doi.org\/10.1056\/nejm199810013391402","journal-title":"N Engl J Med"},{"key":"5755_CR18","doi-asserted-by":"crossref","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. The Cochrane Library","DOI":"10.1002\/14651858.CD005088.pub4"},{"issue":"1","key":"5755_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","volume":"32","author":"L Folkestad","year":"2017","unstructured":"Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2017) Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res 32(1):125\u2013134. https:\/\/doi.org\/10.1002\/jbmr.2920","journal-title":"J Bone Miner Res"},{"issue":"5","key":"5755_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30(5):929\u2013933. https:\/\/doi.org\/10.1002\/jbmr.2410","journal-title":"J Bone Miner Res"},{"key":"5755_CR21","first-page":"367","volume":"6","author":"E Monti","year":"2010","unstructured":"Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F (2010) Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 6:367\u2013381","journal-title":"Ther Clin Risk Manag"},{"key":"5755_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fendo.2019.00375","volume":"10","author":"YJ Cao","year":"2019","unstructured":"Cao YJ, Wei Z, Zhang H, Zhang ZL (2019) Expanding the clinical spectrum of osteogenesis imperfecta type V: 13 additional patients and review. Front Endocrinol 10:375. https:\/\/doi.org\/10.3389\/fendo.2019.00375","journal-title":"Front Endocrinol"},{"issue":"7","key":"5755_CR23","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/jbmr.1891","volume":"28","author":"JR Shapiro","year":"2013","unstructured":"Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SC, Dawson BC, Baldridge DM, Bainbridge MN, Cohn DH, Blazo M, Roberts TT, Brennen FS, Wu Y, Gibbs RA, Melvin P, Campeau PM, Lee BH (2013) Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res 28(7):1523\u20131530. https:\/\/doi.org\/10.1002\/jbmr.1891","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5755_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/jmedgenet-2012-101307","volume":"50","author":"F Rauch","year":"2013","unstructured":"Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM, Ramirez N, Fahiminiya S, Majewski J, Glorieux FH (2013) Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients. J Med Genet 50(1):21\u201324. https:\/\/doi.org\/10.1136\/jmedgenet-2012-101307","journal-title":"J Med Genet"},{"key":"5755_CR25","doi-asserted-by":"publisher","first-page":"100243","DOI":"10.1016\/j.jbo.2019.100243","volume":"17","author":"S Kolovos","year":"2019","unstructured":"Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, Yong K, Ashcroft J, Bowcock S, Drayson MT, Ramasamy K, Prieto-Alhambra D, Cooper C, Javaid MK, Pinedo-Villanueva R (2019) Unplanned admissions for patients with myeloma in the UK: low frequency but high costs. J Bone Oncol 17:100243. https:\/\/doi.org\/10.1016\/j.jbo.2019.100243","journal-title":"J Bone Oncol"},{"key":"5755_CR26","unstructured":"NHS England (2019) NHS inpatient admission and outpatient referrals and attendances 1edn"},{"key":"5755_CR27","unstructured":"Baker C (2020) NHS key statistics: England"},{"key":"5755_CR28","unstructured":"Brittle Bone Society (2020) What is osteogenesis imperfecta? https:\/\/brittlebone.org\/what-is-oi\/about-oi\/. Accessed 27 Aug 2020"},{"issue":"4","key":"5755_CR29","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/EJE-20-0299","volume":"183","author":"R Marom","year":"2020","unstructured":"Marom R, Rabenhorst BM, Morello R (2020) Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol 183(4):R95\u2013R106","journal-title":"Eur J Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05755-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:06:21Z","timestamp":1621267581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05755-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5755"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05755-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RPV has received research funding from Kyowa Kirin Services and lecture fees and\/or consulting honoraria from Amgen, UCB, Kyowa Kirin Services, and Mereo Biopharma. MKJ has received consultancy fees from Mereo Biopharma. SK declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Descriptive statistics were calculated using Excel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}